| Condition |
Trial Name |
Sponsor |
| Solid Tumors |
1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors |
Mirati Therapeutics, Inc. |
| Breast Cancer |
ACE-Breast-03: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects Previously Treated with T-DXd |
Ambrx, Inc. |
| Non-Small Cell Lung Cancer |
ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor |
OSE Immunotherapeutics |
| Breast Cancer |
ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer |
Gilead Sciences, Inc. |
| Cachexia in Colorectal or Pancreatic Cancer |
AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy |
AVEO Pharmaceuticals, Inc. |
| Colon Cancer |
AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer |
GlaxoSmithKline |
| Breast Cancer |
BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer |
BriaCell Therapeutics Corporation |
| Non-Small Cell Lung Cancer |
CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform |
Elephas Biosciences Corporation |
| Breast Cancer and Endometrial Cancer |
DB-1303-O-1001: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors |
DualityBio Inc. |
| Prostate Cancer |
Debio 4228-201: Study of Extended Release GnRH in Newly Diagnosed Locally Advanced or Metastatic Prostate Cancer |
Debiopharm International SA |
| Non-Small Cell Lung Cancer |
EIK1001-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer |
Eikon Therapeutics |
| Breast Cancer |
ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor |
Stemline Therapeutics, Inc. |
| Diffuse Large B-Cell Lymphoma |
EPCORE: Epcoritamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Follicular Lymphoma |
AbbVie Inc. |
| Breast Cancer |
EvoPAR-Breast01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative, BRCA1, BRCA2, or PALB2m Advanced Breast Cancer |
AstraZeneca |
| Prostate Cancer |
EvoPAR-Prostate01: Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents |
AstraZeneca |
| Central Nervous System Cancer |
F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy |
Fore Biotherapeutics |
| Breast Cancer |
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer |
Regor Pharmaceuticals Inc. |
| Gastric or Gastroesophageal Junction Cancer |
GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
AstraZeneca |
| Non-Small Cell Lung Cancer |
KRAScendo-1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
| Non-Small Cell Lung Cancer |
KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation |
Mirati Therapeutics, Inc. |
| Multiple Myeloma |
M22-574: Study of Treatment with Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma After at Least 2 Prior Lines of Therapy |
AbbVie |
| Follicular Lymphoma or Marginal Zone Lymphoma |
MAHOGANY: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/​Refractory Follicular or Marginal Zone Lymphoma |
BeiGene, Ltd. |
| Colorectal Cancer |
MBI-006-COMUNITY: Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer |
Mirror Biologics, Inc. |
| Hyperkalemia/Chronic Kidney Disease |
NYH-01: Hyperkalemia/Chronic Kidney Disease |
Relypsa |
| Breast Cancer |
OPERA-01: OP-1250 (palazestrant) in ER-Positive and HER2-Negative Metastatic Breast Cancer Previously Treated with a CDK4/6 Inhibitor |
Olema Pharmaceuticals, Inc. |
| Advanced Solid tumors |
Phase 1 Study of SGN-B6A in Advanced Solid Tumors |
Seagen Inc. |
| Non-Small Cell Lung Cancer |
Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
Regeneron Pharmaceuticals |
| Multiple Myeloma |
Prospective Observational Study to Evaluate an Electronic Health Record-Based Data Collection Infrastructure for Capturing the Risk Factors for Severe and Fatal Infusion related Reactions in Newly Diagnosed Multiple Myeloma Participants Treated with Daratumumab (Intravenous or Subcutaneous) |
J&J |
| Solid Tumors or Multiple Myeloma |
QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma |
Nammi Therapeutics Inc |
| ITP, wAIHA, CAD |
RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias |
Alpine Immune Sciences, Inc. |
| Diffuse Large B-Cell Lymphoma |
SKYGLO: Glofitamab in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma |
Hoffmann-La Roche |
| Head and Neck Squamous Cell Carcinoma |
STELLAR-305: Zanzalintinib in Combination with Pembrolizumab as First Line Therapy for Recurrent or Metastatic Disease |
Exelixis |
| Multiple Myeloma |
SUCCESSOR-1: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) |
Celgene Corporation |
| Non-Small Cell Lung Cancer |
TRITON: First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology |
AstraZeneca LP |
| Non-Small Cell Lung Cancer |
TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer |
Daiichi Sankyo, Inc. |
| Cancer Diagnosis |
[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients |
Memorial Sloan Kettering Cancer Center |
| Various Indications |
[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) |
Precision for Medicine |
| Solid Tumors |
[Sample Collection] Collection and Distribution of Biofluids for Research Purposes |
Bluestar Genomics |
| Solid Tumors |
[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) |
Exact Sciences Thrive LLC |
| Various Indications |
[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) |
SERATRIALS, LLC. |
| Solid Tumors |
[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening |
Freenome Holdings Inc. |
